Microbot Medical(US:MBOT) Globenewswire·2026-01-12 13:30Core Insights - Microbot Medical Inc. is progressing towards a Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System in Q2 2026, building on positive customer feedback and market enthusiasm [1] - The company achieved significant milestones in 2025, including FDA 510(k) clearance and the initiation of a limited market release [1][4] - The target market for LIBERTY includes approximately 2.5 million peripheral endovascular procedures annually in the U.S. [1] 2025 Operational and Business Achievements - Received FDA clearance for the LIBERTY system, the first single-use, remotely operated robotic system for peripheral endovascular procedures [4] - Launched a Limited Market Release, with Emory University Hospital being the first to adopt the system [4] - Established a commercial leadership team and expanded cross-functional teams to support launch readiness [4] - Presented pivotal trial data showing 100% robotic navigation success and a 92% reduction in radiation exposure [4] - Expanded the intellectual property portfolio with 20 patents granted and 52 applications pending [4] Anticipated 2026 Operational and Commercial Milestones - Full Market Release of the LIBERTY System is set for Q2 2026, coinciding with the Society of Interventional Radiology conference [3][4] - Plans to grow the customer base by attracting early adopters and securing new hospitals for medium-to-high volume procedures [3] - Aims to validate the LIBERTY System's market opportunity by expanding the types of procedures and end-user call points [3] - Establish commercial infrastructure for expansion into international markets [3] - Maintain a strong presence at key medical societies and conferences throughout 2026 [5]